Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Age-related Macular Degeneration Market: By Drug Type, By Disease Type and Geography
Age-related Macular Degeneration Market: By Drug Type, By Disease Type and Geography
Age-related Macular Degeneration Market size was valued at US$ 9,632.8 million in 2022, growing at a CAGR of 7.8% from 2023 to 2029. The global market provides a detailed overview of the global market, and that can be segmented by Drug Type, and by Disease Type. By drug type, the global age-related macular degeneration market has been segmented into Ranibizumab, Aflibercept, Bevacizumab, Pegaptanib, Brolucizumab, and Others. The ranibizumab segment is likely to be the largest and fastest-growing segment in terms of drug type. Based on disease type, the global age-related macular degeneration market is segmented into Wet AMD and dry AMD. Among these, the wet AMD segment is expected to have the fastest-growing market during the forecast period.
Study Period
2024-2030Base Year
2023CAGR
7.8%Largest Market
Asia PacificFastest Growing Market
North America
Drivers: Permanent vision loss is a problem that worsens with time and causes great anxiety for older persons. There are two types of macula wear that result in the condition, both kinds are harmful and require medication. The potential market for age-related macular degeneration is growing as a result of the older age group's increasing demand for treatment
By region, North America is expected to witness the highest market share during the forecast period because of the growing number of ophthalmological conditions and an older population.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2022 |
US$ 9,632.8 million |
|
Market CAGR |
7.8% |
|
By Drug Type |
|
|
By Disease Type |
|
|
By Region |
|
Download Free Sample Report
The global age-related macular degeneration market size is valued at US$ 9,632.8 million in 2022
The major key players of the market are Hoffmann-La Roche AG, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc, ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc., GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals, Inc.
The age related macular degeneration market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Age-related Macular Degeneration Market Introduction |
| 2.1. Global Age-related Macular Degeneration Market Taxonomy |
| 2.2. Global Age-related Macular Degeneration Market Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Disease Type |
| 3. Global Age-related Macular Degeneration Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Age-related Macular Degeneration Market Dynamic Factors - Impact Analysis |
| 3.6. Global Age-related Macular Degeneration Market Competition Landscape |
| 3.7. Epidemiology |
| 4. Global Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Age-related Macular Degeneration Market, By Drug Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Ranibizumab |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Aflibercept |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Bevacizumab |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Pegaptanib |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Brolucizumab |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Age-related Macular Degeneration Market Forecast, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029 |
| 6.1. Wet AMD |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Dry AMD |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Age-related Macular Degeneration Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Region, 2023 - 2029 |
| 8. North America Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. By Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Ranibizumab |
| 8.1.2. Aflibercept |
| 8.1.3. Bevacizumab |
| 8.1.4. Pegaptanib |
| 8.1.5. Brolucizumab |
| 8.1.6. Others |
| 8.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Wet AMD |
| 8.2.2. Dry AMD |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Country, 2023 - 2029 |
| 8.5. North America Age-related Macular Degeneration Market Dynamics Trends |
| 9. Europe Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. By Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Ranibizumab |
| 9.1.2. Aflibercept |
| 9.1.3. Bevacizumab |
| 9.1.4. Pegaptanib |
| 9.1.5. Brolucizumab |
| 9.1.6. Others |
| 9.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Wet AMD |
| 9.2.2. Dry AMD |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Poland |
| 9.3.8. Rest of Europe |
| 9.4. Europe Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Country, 2023 - 2029 |
| 9.5. Europe Age-related Macular Degeneration Market Dynamics Trends |
| 10. Asia-Pacific Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. By Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Ranibizumab |
| 10.1.2. Aflibercept |
| 10.1.3. Bevacizumab |
| 10.1.4. Pegaptanib |
| 10.1.5. Brolucizumab |
| 10.1.6. Others |
| 10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Wet AMD |
| 10.2.2. Dry AMD |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Age-related Macular Degeneration Market Dynamics Trends |
| 11. Latin America Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. By Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Ranibizumab |
| 11.1.2. Aflibercept |
| 11.1.3. Bevacizumab |
| 11.1.4. Pegaptanib |
| 11.1.5. Brolucizumab |
| 11.1.6. Others |
| 11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Wet AMD |
| 11.2.2. Dry AMD |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Country, 2023 - 2029 |
| 11.5. Latin America Age-related Macular Degeneration Market Dynamics Trends |
| 12. Middle East and Africa Age-related Macular Degeneration Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. By Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Ranibizumab |
| 12.1.2. Aflibercept |
| 12.1.3. Bevacizumab |
| 12.1.4. Pegaptanib |
| 12.1.5. Brolucizumab |
| 12.1.6. Others |
| 12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Wet AMD |
| 12.2.2. Dry AMD |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Age-related Macular Degeneration Market - Opportunity Analysis Index, By Drug Type, Disease Type, and Country, 2023 - 2029 |
| 12.5. MEA Age-related Macular Degeneration Market Dynamics Trends |
| 13. Global Age-related Macular Degeneration Market - Pipeline Analysis, 2023 - 2029 |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Bayer AG |
| 13.2.2. F. Hoffmann-La Roche Ltd. |
| 13.2.3. Regeneron Pharmaceuticals |
| 13.2.4. Novartis International AG |
| 13.2.5. Bausch Health Companies Inc. |
| 13.2.6. Pfizer, Inc. |
| 13.2.7. Rxi Pharmaceuticals |
| 13.2.8. Alimera Sciences, Inc. |
| 13.2.9. Valeant Pharmaceutical International, Inc |
| 13.2.10. Acucela, Inc. |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.